For individuals newly diagnosed with HIV, a long-acting injectable treatment regimen is increasingly becoming a preferred alternative to daily oral medications, offering a potential boost to adherence and overall treatment satisfaction. Cabotegravir plus rilpivirine administered as an injection (CAB+RPV LA) is gaining recognition as a versatile option, particularly for those who may struggle with or prefer to avoid a daily pill burden.
Recent data from the phase IIIb VOLITION study demonstrates that a significant majority – 89% (n=129/145) – of treatment-naïve individuals living with HIV opted to switch to long-acting injectable Vocabria + Rekambys following rapid viral suppression with daily Dovato (dolutegravir/lamivudine (DTG/3TC)), according to an announcement from ViiV Healthcare on July 14, 2025. This preference highlights a growing demand for more convenient and patient-centered HIV treatment options.
The appeal of CAB+RPV LA lies in its ability to simplify the treatment process. Instead of taking a pill every day, individuals receive injections, reducing the frequency of medication management and potentially minimizing the stigma associated with daily HIV treatment. This is particularly beneficial for those facing challenges with adherence due to pill counts, privacy concerns, or other personal factors. Daily adherence to oral antiretroviral therapy can be challenging for some individuals due to a variety of complex reasons, including pill burden, disclosure concerns, and stigma.
Effectiveness Across Diverse Populations
Although initially approved as a switch option for virologically suppressed patients, real-world data suggests CAB+RPV LA is effective even in treatment-experienced individuals with detectable viral loads. This versatility expands the potential patient pool who could benefit from this long-acting injectable regimen. Researchers at ViiV Healthcare note that the treatment offers high effectiveness and tolerability, alongside improved adherence and a dosing schedule that many patients identify preferable to daily oral pills.
The U.S. Food and Drug Administration (FDA) initially approved long-acting injectable cabotegravir plus rilpivirine (LA CAB/RPV) as a switch strategy for patients with HIV who are virologically suppressed on oral antiretroviral therapy and have no history of treatment failure . The New York State Department of Health AIDS Institute (NYSDOH AI) has as well developed guidelines for clinicians on the use of CAB/RPV LA as replacement antiretroviral therapy for adults with HIV who are virally suppressed .
Addressing Challenges with Oral Regimens
The development of long-acting injectables represents a significant advancement in HIV treatment, addressing challenges associated with daily oral medications. A study highlighted by suggests that CAB+RPV LA is a preferred treatment for patients who dislike oral regimens and would prefer longer-acting medication to improve adherence. This is further supported by findings that 89% of treatment-naïve individuals with HIV chose to switch to the injectable form after achieving viral suppression with daily pills .
Before initiating CAB+RPV LA, healthcare providers emphasize the importance of education and counseling to prepare patients for potential adverse effects, which typically occur early in treatment. Reassurance that ongoing adverse reactions are likely to diminish in frequency and intensity is also crucial for successful adoption of this new treatment modality.
Looking Ahead
The increasing preference for long-acting injectable HIV treatments like CAB+RPV LA signals a shift towards more patient-centered care and a commitment to improving treatment adherence and satisfaction. As real-world evidence continues to accumulate, these regimens are poised to play an increasingly important role in achieving the ambitious goal of ending the HIV and AIDS epidemic. Further research will likely focus on expanding access to these treatments and optimizing their use across diverse populations.
What are your thoughts on the evolving landscape of HIV treatment? Share your comments below, and please share this article with your network to raise awareness about these advancements.
Disclaimer: This article provides informational content and should not be considered medical advice. Please consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
